Allard Marc Antoine, Sebagh Mylène, Baillie Gaëlle, Lemoine Antoinette, Dartigues Peggy, Faitot François, Faron Matthieu, Boige Valérie, Vitadello Fabrizio, Vibert Eric, Elias Dominique, Adam René, Goéré Diane, Sa Cunha Antonio
Centre Hépato-biliaire, Paul Brousse Hospital, Villejuif Cedex, France.
Ann Surg Oncol. 2015;22(6):1925-32. doi: 10.1245/s10434-014-4272-7. Epub 2014 Dec 2.
Whether hepatic arterial infusion (HAI) of oxaliplatin influences the rates of complete pathologic response (CPR) and severe oxaliplatin-related lesions (SOxL) in patients with colorectal liver metastases (CRLM) is unknown. This study aimed to compare the incidence of CPR and SOxL between systemic (intravenous, IV) and HAI administration.
All patients with initially unresectable CRLM who had undergone hepatic resection in two expert centers between 2004 and 2010 after at least 6 cycles of oxaliplatin-based chemotherapy administered either via HAI (n = 18) or IV (n = 50) were included. The presence of CPR and SOxL were evaluated by two pathologists. A 1:2 case match using a propensity score was used.
A CPR was observed significantly more often after HAI (33 vs. 10 %, P = 0.03). However, SOxL had occurred more frequently in patients in the HAI group versus the IV group, 66 and 20 %, respectively (P < 0.001). On a well-balanced cohort, HAI was associated with higher chance of CPR (odds ratio 9.33, 95 % confidence interval 1.59-54.7) but also higher risk of SOxL (odds ratio 13.7, 95 % confidence interval 3.08-61.3). A CPR markedly enhanced overall survival (OS) and disease-free survival (median OS of 114 vs. 42 months, P = 0.02; median disease-free survival of 51 vs. 12 months, P = 0.002). Patients with SOxL did not experience different outcome (median OS of 42 vs. 50 months, respectively; P = 0.92) CONCLUSIONS: HAI of oxaliplatin increases the likelihood of a CPR at the cost of a higher incidence of SOxL in patients with initially unresectable CRLM.
对于结直肠癌肝转移(CRLM)患者,奥沙利铂肝动脉灌注(HAI)是否会影响完全病理缓解(CPR)率和严重奥沙利铂相关病变(SOxL)尚不清楚。本研究旨在比较全身(静脉注射,IV)给药和HAI给药之间CPR和SOxL的发生率。
纳入2004年至2010年间在两个专家中心接受肝切除的所有初始不可切除CRLM患者,这些患者在接受至少6个周期基于奥沙利铂的化疗后,化疗通过HAI(n = 18)或IV(n = 50)给药。由两名病理学家评估CPR和SOxL的存在情况。采用倾向评分进行1:2病例匹配。
HAI后观察到CPR的频率显著更高(33%对10%,P = 0.03)。然而,HAI组患者中SOxL的发生频率高于IV组,分别为66%和20%(P < 0.001)。在一个均衡的队列中,HAI与更高的CPR几率相关(优势比9.33,95%置信区间1.59 - 54.7),但也有更高的SOxL风险(优势比13.7,95%置信区间3.08 - 61.3)。CPR显著提高了总生存期(OS)和无病生存期(中位OS为114个月对42个月,P = 0.02;中位无病生存期为51个月对12个月,P = 0.002)。有SOxL的患者未经历不同的结局(中位OS分别为42个月对50个月;P = 0.92)
对于初始不可切除的CRLM患者,奥沙利铂HAI增加了CPR的可能性,但代价是SOxL的发生率更高。